

INCJ and 10 portfolio companies in the health and medical field to jointly exhibit at BioJapan 2018

Tokyo, September 26, 2018 – INCJ, Ltd. (“INCJ”) announced today its decision to exhibit at Asia’s leading partnering event in the biotechnology industry, BioJapan 2018, for 3 days between October 10 (Wed.) – 12 (Fri.) at Pacifico Yokohama.

In April 2014, INCJ established a new specialist team covering the health and medical field, which focuses on proactive investment in bio venture companies and supporting the formation and commercialization of ecosystems in this field. Since its establishment in 2009, INCJ has made a total of 133 investments, of this 106 were venture investments and 23 were in the health and medical field. (Figures are as of August 2018.)

INCJ will co-exhibit with its portfolio companies in the health and medical field and participate in partnering activities as usual. Within the exhibition booth, INCJ will showcase panels and posters introducing each company's business outline and technology in order to increase the understanding and awareness of visitors. With regards to partnering, INCJ will explore new possibilities from the introduction of seeds, technology tie-ups and company alliances and conduct networking activities and business meetings.

INCJ will continue to focus on investment activities in the health and medical field and support the steady increase of the value of its portfolio companies and their businesses.

About BioJapan 2018

Event time and date	October 10 (Wed.) -12 (Fri.) 2018 10:00 ~ 17:00 (Partnering from 8:30)
Location	Pacifico Yokohama, Exhibition Hall A/B/C/D 1-1-1 Minato Mirai, Nishi-ku, Yokohama
Website	http://www.ics-expo.jp/biojapan/main/index.html
INCJ exhibition booth location	C-26

Co-exhibitors

• INCJ, Ltd.	
• Anaeropharma Science, Inc. (Development of anti-cancer drugs based on i-DPS platform technology utilizing recombinant Bifidobacterium)	
• ExaWizards Inc. (AI solutions for solving social issues)	
• Curadim Pharma Co., Ltd. (New drug development for intractable diseases)	
• SCOHIA PHARMA, Inc. (Research and development for renal, metabolic and cardiovascular related medicines)	
• Stella Pharma Corporation (Development of boron-based drugs used for Boron Neutron Capture Therapy)	
• Tavelmout Corporation (Development of spirulina cultivation technology and its application, production and sales of spirulina related products)	
• NanoMist Technologies Co., Ltd. (Develops and provides mist-based liquid separation / concentration technology and applied facilities)	
• NapaJen Pharma, Inc. (Development of nucleic acids using unique drug delivery technology)	
• Microwave Chemical Co., Ltd. (R&D, manufacture, engineering and sales including licensing of microwave chemical processes)	
• Rena Therapeutics Inc. (Support of drug discovery centered on heteroduplex oligonucleotide technology)	

About INCJ, Ltd.

INCJ, Ltd. was established in September 2018 via company split from Innovation Network Corporation of Japan (INCJ). INCJ was established in July 2009 with the aim of overcoming boundaries between companies and industries, creating and nurturing key industries via open innovation for the prosperity of future generations, and the company has changed its name to Japan Investment Corporation (JIC) and begun new activities. INCJ, Ltd. will continue the activities of INCJ, engaging in “Value Up” activities such as

overseeing additional investments, milestone investments and exits from investments in portfolio companies until March 2025.

Press contacts:

INCJ, Ltd. Communications, Irie, Sakai

Tel. (03) 5218-7202 URL : <http://www.incj.co.jp/>